<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It is unknown whether the angiotensin receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="9927">valsartan</z:chebi> exerts a renoprotective effect on patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> independent of its hypotensive effects </plain></SENT>
<SENT sid="1" pm="."><plain>Forty patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> participated in this study </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received <z:chebi fb="0" ids="9927">valsartan</z:chebi> 40 mg, a dose with no clinical effect on blood pressure levels </plain></SENT>
<SENT sid="3" pm="."><plain>Blood pressure, urinary albumin excretion (UAE), and <z:chebi fb="0" ids="16737">creatinine</z:chebi> clearance were determined at baseline and at the end of the 6-month treatment period </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="35674">Antihypertensive</z:chebi> and/or <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs, including insulin, were permitted throughout the study </plain></SENT>
<SENT sid="5" pm="."><plain>After 6 months of <z:chebi fb="0" ids="9927">valsartan</z:chebi> therapy, mean UAE decreased from 86.8 +/- 196 to 46.9 +/- 97 microg/min (n = 37) </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, a significant decrease was observed in the UAE of the subgroup of patients displaying diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (UAE &gt; 20 microg/min, n = 14), from 219.4 +/- 275 to 102.7 +/- 141 microg/min, (P &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>Changes in UAE for <z:chebi fb="0" ids="9927">valsartan</z:chebi> correlated significantly with UAE at baseline (r = -0.935, P &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>Serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> levels and <z:chebi fb="0" ids="16737">creatinine</z:chebi> clearance remained stable before and after treatment with <z:chebi fb="0" ids="9927">valsartan</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>No significant differences were observed between pre- and post-treatment body mass index, glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, or systolic and diastolic blood pressure </plain></SENT>
<SENT sid="10" pm="."><plain>In type 2 diabetic patients with diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, 6 months of treatment with low dose <z:chebi fb="0" ids="9927">valsartan</z:chebi>, an <z:chebi fb="0" ids="2719,48432">angiotensin-II</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, thus reduced UAE with no reduction in systemic blood pressure </plain></SENT>
<SENT sid="11" pm="."><plain>The drug may be safely administered in this subset of type 2 diabetic patients </plain></SENT>
<SENT sid="12" pm="."><plain>The long-term benefits in terms of risk reduction must still be evaluated in further trials </plain></SENT>
</text></document>